Certis Oncology Solutions is one of few area laboratories licensed by the California Department of Public Health and Centers for Medicare and Medicaid Services, and is CLIA-certified for high complexity testing, a requirement for compliance with California and US clinical laboratory laws.
That certification, in combination with Certis' in-house molecular biologists and advanced analytical instrumentation, enabled Certis to quickly pivot in response to the COVID-19 pandemic.
The company will offer an FDA-approved viral test, which employs nasopharyngeal swabbing and Reverse Transcription Polymerase Chain Reaction (RT-PCR) analyses, widely considered to be the gold standard in biological identification.
Certis will bring testing to individual work sites--minimizing exposure risk and reducing employees' time away from work.
Nasopharyngeal swabbing is performed by Licensed Practice Nurses, and samples are analyzed in Certis' Sorrento Valley-based laboratory.
The company aims to deliver results in 24-48 hours.
Certis Oncology Solutions was formed in 2016 with the mission to provide individualised treatment options to cancer patients.
Its technology enables oncologists to determine with precision the most effective available therapies to treat each patient's unique disease.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories